Among the immune evasion mechanisms of cancer cells, the interaction between programmed cell death 1 (PD1) and programmed death-ligand 1 (PD-L1) is critical and important in cancer treatment because immune checkpoint inhibitors targeting PD1/PD-L1 show therapeutic efficacy [13,14]. This evidence concerns the gene PDCD1 and cancer.